title: [Coagulation and fibrinolysis in pregnancy].
abstract: We studied on coagulation and fibrinolysis systems during pregnancy by measuring plasma levels of thrombin-antithrombin III complex (TAT), plasmin-alpha 2 plasmin inhibitor complex (PIC), fibrinogen/fibrin degradation products (FDP), plasminogen (PLG) and antithrombin III (AT-III). Ninety seven pregnant, 5 post-delivery and 32 nonpregnant women aged from 20 to 52 years old were included in this study. Plasma concentrations of TAT and PIC in nonpregnant women were 3.38 +/- 1.02 micrograms/l and 0.65 +/- 0.24 micrograms/ml, respectively. TAT gradually increased with the progression of pregnancy and rapidly decreased after the delivery. Whereas PIC and AT-III concentrations did not change significantly during pregnancy. Fibrinogen, PLG and FDP concentrations changed similarly as TAT. Eight pregnants whose plasma PIC concentrations elevated more than 1.0 micrograms/l were further examined. In 6 women out of them (71.5%), FDP concentrations were elevated. In this particular group of subjects, however, they delivered normally without complications such as toxemia. These observations suggest that, at least, a hypercoagulative state progresses with pregnancy, being normalized after the delivery. Although we could not find the relationship between the hypercoagulation and clinical complications such as thrombosis and toxemia of pregnancy, present findings suggest that special caution should be paid on the pregnants whose TAT and FDP levels are elevated.
authors.affiliation: Section of Clinical Laboratory, University Hospital, Kyoto Prefectural University of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Yuasa
authors.forename: M
authors.initials: M
authors.lastname: Ishizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Yuki
authors.forename: T
authors.initials: T
authors.lastname: Minoura
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Yoshimura
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: H
authors.initials: H
authors.lastname: Okada
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011247:Pregnancy / Q000097:blood*; D000979:alpha-2-Antiplasmin / Q000032:analysis; D000511:alpha-Macroglobulins / Q000032:analysis
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; C046193:antithrombin III-protease complex; C024668:plasmin-alpha(2)-macroglobulin complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin